|Bid||46.06 x 800|
|Ask||46.65 x 1200|
|Day's range||43.08 - 46.50|
|52-week range||25.31 - 141.01|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021 - 13 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||81.17|
George Scangos, President and CEO of Vir Biotechnology, joined Yahoo Finance to discuss the latest on the company's covid-19 antibody treatment.
Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.